Omnio AB attracts EUR 1.5 million in capital investment and aims for first clinical trials in 2024

The drug could mean a global treatment revolution for wounds that never heal. Now, the Umeå-based biopharmaceutical company Omnio AB has received a capital injection of 1.5 million euros from its shareholders that will be used for ongoing development work and to begin creating a blueprint for manufacturing.

Although several key milestones remain before Omnio’s injectable drug is approved and ready for mass production, there have already been a number of physician-led studies and successful trials involving patients with clinical wounds.

Ulrika Norin, CEO of Omnio, has seen for herself what a difference the company’s new treatment can make to patients.

“It is unbelievable what some people have to go through and how restricted they are by their wounds. One of our patients suffered with an ulcer for nine years, but got better after plasminogen treatment", she says.

Omnio raised the additional EUR 1.5 million (approximately SEK 15.8 million) from its shareholders, adding to the approximately SEK 26 million it has received from investors and shareholders over the past year, as well as getting financial support from Sweden’s innovation agency Vinnova.

Thanks to a new share issue of SEK 5.5 million in December last year, Omnio has been able to start working with a contract manufacturer. Now the company can go even further and develop a manufacturing process at the beginning of next year - a prerequisite for starting the preclinical program required to initiate a clinical trial. Omnio aims for its first clinical trials in 2024. 

“It’s very positive to have the continued support of our shareholders, that they believe in the potential of our company and that the treatment we are developing can make a significant difference. Now we have the opportunity to grow even more as a company and form our organisation”, says Ulrika Norin, and continues:

“We expect our treatment to be able to both speed up the wound healing process and prevent patients from having to face amputations. We have a long way to go and need to conduct a controlled clinical trial to show that it really works, but the mechanism for how plasminogen works in the wound healing process is proven and very well documented”.

For more information please contact:

Ulrika Norin, CEO Omnio
+46-739 69 09 30
ulrika.norin@omnio.se

ABOUT OMNIO AB

● Omnio AB is a spin-off company from Umeå University, focusing on wound healing.

● The company’s work is founded on a series of conceptual breakthroughs in plasminogen research led by Professor Tor Ny at Umeå University.

● Omnio has shown that plasminogen is a pro-inflammatory regulator of inflammation that can be used to treat chronic wounds with dysfunctional inflammation.

● Non-healing chronic wounds are a major global health problem and pose a burden to patients, healthcare professionals, and the healthcare system as a whole. The most problematic are diabetic ulcers, venous ulcers, and pressure ulcers.

● Ten million people per year have amputations due to non-healing diabetic foot ulcers (DFU). More than 50 percent of all lower limb amputations are caused by DFU.